How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about slow-release potassium bicarbonate and potassium citrate

Marketing authorisation indication

2.1 Slow-release potassium bicarbonate–potassium citrate (Sibnayal, Advicenne) is indicated for 'the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older.'

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for slow-release potassium bicarbonate–potassium citrate.

Price

2.3 The company's list price is £360.00 per pack of 60 sachets of 24 milliequivalent (mEq) prolonged-release granules or £120.00 per pack of 60 sachets of 8 mEq prolonged-release granules (company submission, excluding VAT). The company has a commercial arrangement (simple discount PAS), which would have applied if the technology had been recommended.